Literature DB >> 7734309

Pathological prognostic factors in the second British Stomach Cancer Group trial of adjuvant therapy in resectable gastric cancer.

C C Yu1, D A Levison, J A Dunn, L C Ward, M Demonakou, W H Allum, M T Hallisey.   

Abstract

The second British Stomach Cancer Group trial was a prospective randomised controlled trial of adjuvant radiotherapy or cytotoxic chemotherapy after gastrectomy for adenocarcinoma. It recruited between 1981 and 1986. No survival advantage has been demonstrated for the patients receiving either type of adjuvant therapy compared with those undergoing surgery alone. We report on 436 patients randomised into the trial together with 203 patients, who did not fulfil the trial criteria, referred to the trial. A univariate (log-rank) analysis of pathological factors obtained from the local referring centres showed that tumour size, macroscopic type, number os sites involved, depth of invasion, involvement of resection lines and lymph nodes and histological grade were significant determinants of survival. Histological review by two experienced histopathologists found that the Lauren classification and histological grade, but not the Ming classification, were significant prognostic factors. The degree of lymphocytic and eosinophilic infiltration and presence of dysplasia assessed by one of the pathologists showed a significant correlation with survival. However, inter-observer correlation for these histological parameters and grade was poor. Multivariate analysis identified only depth of invasion, resection line and nodal involvement as significant independent pathological variables influencing survival. This study confirms the need for expert preparation of the resected specimen to obtain the important information on depth of invasion and nodal status and also reveals some variation in histological assessment, particularly grading, in gastric carcinoma.

Entities:  

Mesh:

Year:  1995        PMID: 7734309      PMCID: PMC2033774          DOI: 10.1038/bjc.1995.214

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  19 in total

1.  Quantitative analysis of nodal involvement with respect to survival rate after curative gastrectomy for carcinoma.

Authors:  T Okusa; Y Nakane; T Boku; H Takada; M Yamamura; K Hioki; M Yamamoto
Journal:  Surg Gynecol Obstet       Date:  1990-06

2.  Gastric carcinoma. A pathobiological classification.

Authors:  S C Ming
Journal:  Cancer       Date:  1977-06       Impact factor: 6.860

3.  Gastric adenocarcinoma: prognostic significance of several pathologic parameters and histologic classifications.

Authors:  K Davessar; J C Pezzullo; N Kessimian; J H Hale; H O Jauregui
Journal:  Hum Pathol       Date:  1990-03       Impact factor: 3.466

4.  Factors influencing survival in patients with cancer of the stomach. A multivariate analysis.

Authors:  O Søreide; J Lillestøl; A Viste; T Bjerkeset
Journal:  Acta Chir Scand       Date:  1982

5.  Prognosis of gastric carcinoma after curative surgery. A population-based study using multivariate crude and relative survival analysis.

Authors:  P Arveux; J Faivre; M C Boutron; F Piard; L Dusserre-Guion; E Monnet; P Hillon
Journal:  Dig Dis Sci       Date:  1992-05       Impact factor: 3.199

6.  Evaluation of histological classification in early gastric cancer (an analysis of 300 cases).

Authors:  K Elster; W Carson; A Wild; A Thomasko
Journal:  Endoscopy       Date:  1979-09       Impact factor: 10.093

7.  Norwegian multicentre study of survival and prognostic factors in patients undergoing curative resection for gastric carcinoma. The Norwegian Stomach Cancer Trial.

Authors:  T K Haugstvedt; A Viste; G E Eide; O Söreide
Journal:  Br J Surg       Date:  1993-04       Impact factor: 6.939

8.  Pathology and prognosis of gastric carcinoma. Findings in 10,000 patients who underwent primary gastrectomy.

Authors:  K Nakamura; T Ueyama; T Yao; Z X Xuan; K Ambe; Y Adachi; Y Yakeishi; A Matsukuma; M Enjoji
Journal:  Cancer       Date:  1992-09-01       Impact factor: 6.860

9.  Prognostic significance of Lauren and Ming classifications and other pathologic parameters in gastric carcinoma.

Authors:  M M Ribeiro; J A Sarmento; M A Sobrinho Simões; J Bastos
Journal:  Cancer       Date:  1981-02-15       Impact factor: 6.860

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

View more
  20 in total

1.  Prognostic significance of host- and tumor-related factors in patients with gastric cancer.

Authors:  Yasuhiko Mohri; Kouji Tanaka; Masaki Ohi; Takeshi Yokoe; Chikao Miki; Masato Kusunoki
Journal:  World J Surg       Date:  2010-02       Impact factor: 3.352

2.  Intravenous chemotherapy for resected gastric cancer: meta-analysis of randomized controlled trials.

Authors:  Jian-Kun Hu; Zhi-Xin Chen; Zong-Guang Zhou; Bo Zhang; Jing Tian; Jia-Ping Chen; Li Wang; Chao-Hua Wang; Hong-Yan Chen; You-Ping Li
Journal:  World J Gastroenterol       Date:  2002-12       Impact factor: 5.742

Review 3.  Hyperthermic intraperitoneal chemotherapy in prevention of gastric cancer metachronous peritoneal metastases: a systematic review.

Authors:  Mikhail Yu Reutovich; Olga V Krasko; Oleg G Sukonko
Journal:  J Gastrointest Oncol       Date:  2021-04

4.  Expression of thymidylate synthase determines the response of gastric cancer patients undergoing gastrectomy to 5-fluorouracil-based adjuvant chemotherapy.

Authors:  Chun-Nan Yeh; Shih-Ming Jung; Tsung-Wen Chen; Tsann-Long Hwang; Yi-Yin Jan; Miin-Fu Chen
Journal:  Langenbecks Arch Surg       Date:  2009-12-10       Impact factor: 3.445

5.  Hyperthermic intraperitoneal chemotherapy (HIPEC) and neoadjuvant chemotherapy as prophylaxis of peritoneal carcinosis from advanced gastric cancer-effects on overall and disease free survival.

Authors:  Federico Coccolini; Andrea Celotti; Marco Ceresoli; Giulia Montori; Michele Marini; Fausto Catena; Luca Ansaloni
Journal:  J Gastrointest Oncol       Date:  2016-08

6.  Risk factors of survival and surgical treatment for advanced gastric cancer with large tumor size.

Authors:  Chen Li; Sung Jin Oh; Sungsoo Kim; Woo Jin Hyung; Min Yan; Zheng Gang Zhu; Sung Hoon Noh
Journal:  J Gastrointest Surg       Date:  2009-01-31       Impact factor: 3.452

7.  Effectiveness of plasma treatment on gastric cancer cells.

Authors:  Koji Torii; Suguru Yamada; Kae Nakamura; Hiromasa Tanaka; Hiroaki Kajiyama; Kuniaki Tanahashi; Naoki Iwata; Mitsuro Kanda; Daisuke Kobayashi; Chie Tanaka; Tsutomu Fujii; Goro Nakayama; Masahiko Koike; Hiroyuki Sugimoto; Shuji Nomoto; Atsushi Natsume; Michitaka Fujiwara; Masaaki Mizuno; Masaru Hori; Hideyuki Saya; Yasuhiro Kodera
Journal:  Gastric Cancer       Date:  2014-07-06       Impact factor: 7.370

Review 8.  Pathohistological classification systems in gastric cancer: diagnostic relevance and prognostic value.

Authors:  Felix Berlth; Elfriede Bollschweiler; Uta Drebber; Arnulf H Hoelscher; Stefan Moenig
Journal:  World J Gastroenterol       Date:  2014-05-21       Impact factor: 5.742

Review 9.  Peritoneal carcinomatosis.

Authors:  Federico Coccolini; Federico Gheza; Marco Lotti; Salvatore Virzì; Domenico Iusco; Claudio Ghermandi; Rita Melotti; Gianluca Baiocchi; Stefano Maria Giulini; Luca Ansaloni; Fausto Catena
Journal:  World J Gastroenterol       Date:  2013-11-07       Impact factor: 5.742

10.  Adjuvant chemotherapy for elderly patients with gastric cancer after D2 gastrectomy.

Authors:  Ying Jin; Miao-zhen Qiu; De-shen Wang; Dong-sheng Zhang; Chao Ren; Long Bai; Hui-yan Luo; Zhi-qiang Wang; Feng-hua Wang; Yu-hong Li; Rui-hua Xu
Journal:  PLoS One       Date:  2013-01-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.